Fig. 3

Gender and stage could influence the immune cells in cancer patients. (A-B) The absolute number and percentage of CD16⁺CD56⁺ NK cells in male (n = 770) and female (n = 605) cancer patients. (C-D) The absolute number and percentage of CD19⁺ B cells in male and female patients. (E-F) The percentage of CD3⁺CD4⁺ Th cells and the ratio of CD4⁺/CD8⁺ T cells in two groups. (G-L) The absolute number of CD45⁺ cells, CD3⁺ T cells, CD3⁺CD4⁺ Th cells, CD3⁺CD8⁺ CTL, CD16⁺ CD56⁺ NK cells, and CD19⁺ B cells among early (n = 64), middle (n = 386) and late stage (n = 925) of cancer patients. Data were shown as mean ± SEM. Statistic differences between two groups were detected by unpaired t-tests. As for data containing more than two groups, they were compared by one-way ANOVA test followed by the Turkey test. P values were indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001